anti10a Levels in Women Treated With LMWH in the Postpartum Period

• Status: Not yet recruiting
• Trial end date: 2022-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this study is to compare between anti-10a levels in postpartum women receiving different prophylactic doses of LMWH: one group with LMWH doses adjusted by the women's weight and the second group receiving 1mg/kg to a maximum dose of 120 mg

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: HaEmek Medical Center, Israel
• Treatments: Enoxaparin

Criteria

Inclusion Criteria:

• postpartum women supposed to receive LMWH according to obstetric indications

Exclusion Criteria:

• known allergy to clexane

• active bleeding postpartum

• thrombocytopenia < 75000

• recent cerebrovascular accident / transient ischemic attack (<4 weeks)

• glomerular filtration rate) < 30 ml/min)

• active liver disease

• malignant hypertension (systolic > 200 mmHg, diastolic> 120 mmHg)